ACLERASTIDE

Description
Sources: https://adisinsight.springer.com/drugs/800027333 | https://www.ncbi.nlm.nih.gov/pubmed/30012502 | https://www.ncbi.nlm.nih.gov/pubmed/26029484 | https://www.biospace.com/article/derma-sciences-ceo-b-edward-quilty-b-resigns-following-trial-failure-/

Aclerastide (DSC-127; NorLeu-3-A(1-7)) is an angiotensin analogue that is being developed by Derma Sciences (a subsidiary of Integra LifeSciences) for the treatment for wounds such as diabetic foot ulcer and surgical scars. The mechanisms of action include induction of progenitor proliferation, accelerated vascularization, collagen deposition, and re-epithelialization. Aclerastide recently failed in phase III clinical trials for treatment of diabetic foot ulcers. Phase I development of aclerastide ophthalmic solution is ongoing in the US.

Originator

Approval Year

PubMed

Title	Date	PubMed
NorLeu(3)-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers.	2015 Jun 1	26029484
Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers.	2018 Sep 5	30012502

Sample Use Guides

In Vivo Use Guide

Aclerastide 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days

Route of Administration: Topical

Name

Type

Language

ACLERASTIDE

Official Name

English

DSC-127

Common Name

English

NORLEU3-ANGIOTENSIN(1-7)

Common Name

English

Aclerastide [WHO-DD]

Common Name

English

DSC127

Code

English

USB-001

Code

English

NORLEU3-A(1-7)

Common Name

English

USB005

Code

English

USB-005

Code

English

ASP-ARG-NLE-TYR-ILE-HIS-PRO

Common Name

English

aclerastide [INN]

Common Name

English

1-7-ANGIOTENSIN II, 3-L-NORLEUCINE-5-L-ISOLEUCINE

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

414813